Le Lézard
Classified in: Health
Subject: EXE

Government of Canada addressing the opioid crisis through research


A further $1.8 M invested at the CRCHUM (Centre de recherche du Centre hospitalier de l'Université de Montréal) re-affirms life-saving opioids research in Quebec and the Maritimes

MONTREAL, Dec. 11, 2017 /CNW/ - The Honourable Ginette Petitpas Taylor, Minister of Health, met with researchers at the Quebec and Maritimes Node of the Canadian Research Initiative in Substance Misuse (CRISM) in Montreal today. This research team is working to advance the Government of Canada's response to the ongoing opioid crisis.

The Minister recently announced $7.5 million in funding to support the important work of CRISM. This funding is being divided equally among the four regional nodes. Of this funding, more than $1.8 million is being provided to the Quebec and Maritimes Node, based at the Centre de recherche du Centre hospitalier de l'Université de Montréal.

Led by Dr. Julie Bruneau, the Quebec and Maritimes node is building research capacity and connecting researchers and Indigenous partners in five provinces. Among other priorities, the network focuses on harm-reduction initiatives, and addressing barriers to intervention and treatment of substance use disorders and mental health issues.

The Minister met with the research team and discussed recent clinical discoveries related to effective treatments, such as a community-based naloxone administration training programs for substance users and their peers as well as stigma-reduction efforts.

Quotes

"The work being carried out by the CRISM research team here in Montreal is representative of Canada's response to our most pressing of public health crises. The knowledge and strategies being developed will translate into more effective responses, and will ultimately help save lives all across Canada."
Ginette Petitpas Taylor
Minister of Health

"Investments in CRISM will speed up the development and implementation of science-based interventions so that overdose deaths can be prevented, those with opioid dependency receive effective treatments and that we reach those populations most at risk."
Dr. Samuel Weiss
Scientific Director of the CIHR Institute of Neurosciences, Mental Health and Addiction

"We are proud to be working at finding solutions to this most pressing health issue. Our researchers are developing effective treatments and methodologies to address the many challenges associated with harmful substance use."
Dr. Julie Bruneau
Nominated Principal Investigator, CRISM

Related Products

CRISM Announcement

Associated Links

At the Canadian Institutes of Health Research (CIHR) we know that research has the power to change lives. As Canada's health research investment agency, we collaborate with partners and researchers to support the discoveries and innovations that improve our health and strengthen our health care system.

 

SOURCE Canadian Institutes of Health Research


These press releases may also interest you

at 14:08
Seacoast Laboratory Data Systems, a nationwide leader in providing customizable LIS and AR software solutions for commercial and...

at 14:05
The Atrium at Cardinal Drive, a Benchmark Mind & Memory Care community, has ranked among the best assisted living with memory care communities in Massachusetts and the entire U.S. for the second straight year. In U.S. News & World Report's third...

at 14:04
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) is proud to announce the recipients of the 2024 ADLM and Academy of Diagnostics & Laboratory Medicine Awards. Through this annual awards program, ADLM and its Academy...

at 14:04
Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and...

at 14:00
Help at Home, the leading national provider of innovative, high-quality, home care services, today announced that it is encouraged by the Administration's continued recognition of the value of the home care industry and its critical role in support...

at 13:46
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into distribution agreements for VETIGEL® to be sold through several leading regional distributors of...



News published on and distributed by: